Sagimet Biosciences, Inc. Class A, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Brandon Folkes from H.C. Wainwright reiterated a Buy rating on the stock and has a $29.00 price target.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Brandon Folkes has given his Buy rating due to a combination of factors, chiefly the attractive risk/reward profile he sees in Sagimet’s pipeline as it advances programs in both MASH and acne. He argues that the company’s current valuation does not fully reflect the potential of its cirrhotic MASH strategy or the optionality from its emerging acne franchise, creating room for substantial upside.
Folkes also points to concrete clinical and regulatory catalysts that could drive value over the next 12–18 months, including a planned Phase 2 proof‑of‑concept trial of denifanstat plus resmetirom in F4 MASH following a favorable Phase 1 safety and pharmacokinetic study. He highlights the mechanistic synergy of FASN inhibition with THR‑β agonism and early evidence of fibrosis improvement as reasons to view the combination as a potential best‑in‑class option in a high‑need population, reinforcing his conviction in the Buy rating and $29 price target.
According to TipRanks, Folkes is a 2-star analyst with an average return of 0.2% and a 39.40% success rate. Folkes covers the Healthcare sector, focusing on stocks such as Cormedix, MannKind, and Omeros.